High-dose dexamethasone modulates serum cytokine profile in patients with primary immune thrombocytopenia

Immunology Letters

Volumn 160, Issue 1, 2014, Pages 33-38

  Zhan, Yanxia ^a   Zou, Shanhua ^a   Hua, Fanli ^a   Li, Feng ^a   Ji, Lili ^a   Wang, Weiguang ^a   Ye, Yi ^a   Sun, Lihua ^b   Chen, Hao ^c   Cheng, Yunfeng ^a,b  

^a FUDAN UNIVERSITY   (China)

^b ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^c TONGJI UNIVERSITY   (China)

Author keywords

Cytokine profile; High dose dexamethasone; Modulate; Primary immune thrombocytopenia

Indexed keywords

CYTOKINE; DEXAMETHASONE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH RELATED ONCOGENE PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; MALE; PRIMARY IMMUNE THROMBOCYTOPENIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RELAPSE; REMISSION; TREATMENT DURATION; BLOOD; CASE CONTROL STUDY; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; THROMBOCYTE COUNT; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; CASE-CONTROL STUDIES; CYTOKINES; DEXAMETHASONE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84921945496     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2014.03.002     Document Type: Article

References (29)

1. Mathias S.D., Bussel J.B., George J.N., McMillan R., Okano G.J., Nichol J.L. A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health Qual Life Outcomes 2007, 5:11.
2. Schoonen W.M., Kucera G., Coalson J., Li L., Rutstein M., Mowat F., et al. Epidemiology of immune thrombocytopenic purpura in the general practice research database. Br J Haematol 2009, 145:235-244.
3. Rodeghiero F., Stasi R., Gernsheimer T., Michel M., Provan D., Arnold D.M., et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009, 113:2386-2393.
4. Stasi R., Del P.G., Stipa E., Evangelista M.L., Trawinska M.M., Cooper N., et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007, 110:2924-2930.
5. Yadav D., Sarvetnick N. Cytokines and autoimmunity: redundancy defines their complex nature. Curr Opin Immunol 2003, 15:697-703.
6. Rhodus N.L., Cheng B., Ondrey F. Th1/Th2 cytokine ratio in tissue transudates from patients with oral lichen planus. Mediators Inflamm 2007, 198:54.
7. Jabbari A., Suarez-Farinas M., Fuentes-Duculan J., Gonzalez J., Cueto I., Franks A.J., et al. Dominant Th1 and minimal Th17 skewing in discoid lupus revealed by transcriptomic comparison with psoriasis. J Invest Dermatol 2014, 10.1038/jid.2013.269.
8. Wei J., Zheng M., Liang P., Wei Y., Yin X., Tang Y., et al. Apolipoprotein E and its mimetic peptide suppress Th1 and Th17 responses in experimental autoimmune encephalomyelitis. Neurobiol Dis 2013, 56:59-65.
9. Pekiner F.N., Demirel G.Y., Borahan M.O., Ozbayrak S. Cytokine profiles in serum of patients with oral lichen planus. Cytokine 2012, 60:701-706.
10. Guo C., Chu X., Shi Y., He W., Li L., Wang L., et al. Correction of Th1-dominant cytokine profiles by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura. J Clin Immunol 2007, 27:557-562.
11. Wang T., Zhao H., Ren H., Guo J., Xu M., Yang R., et al. Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica 2005, 90:914-923.
12. Andersson P.O., Stockelberg D., Jacobsson S., Wadenvik H. A transforming growth factor-beta1-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura. Ann Hematol 2000, 79:507-513.
13. Shariatmadar S., Nassiri M., Vincek V. Effect of plasma exchange on cytokines measured by multianalyte bead array in thrombotic thrombocytopenic purpura. Am J Hematol 2005, 79:83-88.
14. Webber N.P., Mascarenhas J.O., Crow M.K., Bussel J., Schattner E.J. Functional properties of lymphocytes in idiopathic thrombocytopenic purpura. Hum Immunol 2001, 62:1346-1355.
15. Yu J., Heck S., Patel V., Levan J., Yu Y., Bussel J.B., et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 2008, 112:1325-1328.
16. Szodoray P., Alex P., Chappell-Woodward C.M., Madland T.M., Knowlton N., Dozmorov I., et al. Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system. Rheumatology (Oxford) 2007, 46:417-425.
17. Al-Harthi F., Zouman A., Arfin M., Tariq M., Al-Asmari A. Tumor necrosis factor-alpha and -beta genetic polymorphisms as a risk factor in Saudi patients with vitiligo. Genet Mol Res 2013, 12:2196-2204.
18. Spadaro A., Rinaldi T., Riccieri V., Valesini G. Taccari E. Interleukin 13 in synovial fluid and serum of patients with psoriatic arthritis. Ann Rheum Dis 2002, 61:174-176.
19. Lisi S., Sisto M., Lofrumento D.D., D'Amore M., De Lucro R., Ribatti D. A potential role of the GRO-alpha/CXCR2 system in Sjogren's syndrome: regulatory effects of pro-inflammatory cytokines. Histochem Cell Biol 2013, 139:371-379.
20. Zwerina J., Redlich K., Schett G., Smolen J.S. Pathogenesis of rheumatoid arthritis: targeting cytokines. Ann N Y Acad Sci 2005, 1051:716-729.
21. Cheng Y., Wong R.S., Soo Y.O., Chui C.H., Lau F.Y., Chan N.P., et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 2003, 349:831-836.
22. Stahn C., Lowenberg M., Hommes D.W., Buttgereit F. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol 2007, 275:71-78.
23. Liu X.G., Ma S.H., Sun J.Z., Ren J., Shi Y., Sun L., et al. High-dose dexamethasone shifts the balance of stimulatory and inhibitory Fcgamma receptors on monocytes in patients with primary immune thrombocytopenia. Blood 2011, 117:2061-2069.
24. Panitsas F.P., Theodoropoulou M., Kouraklis A., Karakantza M., Theodorou G.L., Zoumbos N.C., et al. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood 2004, 103:2645-2647.
25. Jin C.Q., Liu F., Dong H.X., Zhang J., Zhou J.W., Song L., et al. Type 2 polarized immune response holds a major position in Epstein-Barr virus-related idiopathic thrombocytopenic purpura (EBV-ITP). Int J Lab Hematol 2012, 34:164-171.
26. Ramirez F., Fowell D.J., Puklavec M., Simmonds S., Mason D. Glucocorticoids promote a TH2 cytokine response by CD4+ T cells in vitro. J Immunol 1996, 156:2406-2412.
27. Shan N.N., Zhu X.J., Wang Q., Wang C.Y., Qin P., Peng J., et al. High-dose dexamethasone regulates interleukin-18 and interleukin-18 binding protein in idiopathic thrombocytopenic purpura. Haematologica 2009, 94:1603-1607.
28. Cines D.B., McMillan R. Management of adult idiopathic thrombocytopenic purpura. Annu Rev Med 2005, 56:425-442.
29. Adcock I.M., Brown C.R., Gelder C.M., Shirasaki H., Peters M.J., Barnes P.J. Effects of glucocorticoids on transcription factor activation in human peripheral blood mononuclear cells. Am J Physiol 1995, 268:C331-C338.